Head and Neck Steering Committee

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

The NCI Head and Neck Steering Committee (HNSC) was established in 2007.

Mission Statement

The HNSC functions to harmonize an efficient, cost-effective, science-driven, and transparent process that will identify and promote the "Best Science" in head and neck clinical research by addressing the design and prioritization of phase 3 trials in head and neck cancer and large phase 2 studies.

Roster of Head and Neck Steering Committee (HNSC) members


2015 Head and Neck Steering Committee Strategic Priorities

Task Forces

  • Metastatic/Recurrent Disease: Christine Chung, M.D. and Brian Nussenbaum, M.D., Co-chairs
  • Previously-untreated Locally Advanced Disease: Avraham Eisbruch, M.D. and A. Dimitrios Colevas, M.D., Co-chairs
  • Rare Tumors: Nabil F. Saba, M.D.and Erich M. Sturgis, M.D., M.P.H., Co-chairs

HNSC Activities

Clinical Trials Planning Meetings (CTPMs)

Clinical Trials

The following are clinical trials that were approved at the concept stage by the Steering Committee:

Trial ID NCT ID Trial Title
ECOG-1311 NCT01824823 A Randomized Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence
ECOG-3311 NCT01898494 Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT with Biomarker Correlatives in Resectable p16+ Locally Advanced Oropharynx Cancer
RTOG-1216 NCT01810913 Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin Versus Docetaxel Versus Cetuximab and Docetaxel for High-Risk Squamous Cell Cancer of the Head and Neck
RTOG-1016 NCT01302834 Phase II-III Trial of Moderate De-Escalation of Chemotherapy and Radiation in Favorable Risk, Locally Advanced, HPV-Associated Oropharynx Cancer
RTOG-1008 NCT01220583 A Randomized Phase II Study of Adjuvant Concurrent Chemotherapy and Radiation in Resected High-Risk Malignant Salivary Gland Tumors
ACRIN-6685 NCT00983697 FDG PET/CT Staging of Head and Neck Cancer and its Impact on the N0 Neck
RTOG-0920 NCT00956007 Phase III Randomized Study of Adjuvant Intensity-Modulated Radiotherapy with Versus Without Cetuximab in Patients With Locally Advanced Resected Squamous Cell Carcinoma of the Head and Neck

Find all NCI-sponsored clinical trials.

CCCT Contact: Jean M. Lynn, RN, M.P.H., OCN